NUVB

Nuvation Bio Class A (NUVB)

About Nuvation Bio Class A (NUVB)

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Details

Daily high

$2.76

Daily low

$2.57

Price at open

$2.60

52 Week High

$4.16

52 Week Low

$1.43

Market cap

904.7M

Dividend yield

0.00%

Volume

9.2M

Avg. volume

2.6M

P/E ratio

-1.23

Nuvation Bio Class A News